Laquinimod is an investigational drug that has not been approved by regulatory authorities, such as the FDA and is under research. The purpose of this study is to determine the safety and effectiveness of the drug laquinimod in treating Primary Progressive Multiple Sclerosis (PPMS) - specifically, in reducing the loss of brain volume and reducing MS worsening. The study will investigate if daily oral treatment with laquinimod capsules (0.6 mg or 1.5 mg) improves outcomes in PPMS.
Who may be Eligible
Age 25-55, inclusive; confirmed and document PPMS diagnosis; magnetic resonance imaging (MRI) showing lesions consistent with PPMS in either or both brain and spinal cord; Expanded Disability Status Scale (EDSS) score of 3 to 6.5 inclusive; documented evidence of clinical disability progression in previous 2 years; Functional System Score (FSS) of = for the pyramidal system or gait impairment due to lower extremity dysfunction.